Skip to main content
OpenTrials
Completed

NCT Number: NCT02397733

Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL)

The main objective of this study i sto evaluate the impact of prophylactic cranial irradiation (PCI) with hippocampal avoidance in the neurocognitive function and quality of life of small cell lung cancer patients.

In addition, the trial assesses the potential changes in hippocampal volumetry due to cranial irradiation using magnetic resonance imaging.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Del Mar. Radiation Oncology Department

Barcelona, 08009, Spain

About this study

Prophylactic cranial irradiation (PCI) has become a standard of care for selected patients with limited and extensive stage small cell lung cancer (SCLC) who have shown benefit after chemotherapy with or without thoracic radiotherapy.

Because hippocampal involvement by metastatic disease is rare, and because preclinical and clinical evidence suggests that radiation dose received by the hippocampus during whole brain radiotherapy may play a role in radiation-induced neurocognitive decline, sparing of the hippocampus during the administration of PCI should result in lower rates of memory loss.

Previous studies have demonstrated the dosimetric capabilities of intensity modulated radiation therapy (IMRT) to conformably avoid the hippocampus without detriment to the radiation dose the remaining brain receives.

The main objective of this trial is compare neurocognitive functioning following hippocampal avoidance PCI to standard PCI treatment measured by Free and Cued Selective Reminding Test (FCSRT). The FCSRT measures verbal learning and memory. The FCSRT emphasizes encoding specificity during learning and recall. One of the secondary objectives of this trial is to test the hypothesis that the lowered neurocognitive function of the patients is due to a substantial reduction in hippocampal volume in magnetic resonance imaging (MRI). Others objectives are to evaluate quality of life (QoL) and the rate of metastases in the hippocampus.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • New diagnosed cytological or histologically confirmed Small cell lung carcinoma (stage I-IV) candidate for PCI, for example, without progressive disease after chemo-radiotherapy in stage I-III or after response after chemotherapy in stage IV
  • Performance status ≤ 1
  • Negative MRI of the brain within one month before protocol entry
  • Patient must give written informed consent before registration

Exclusion criteria

  • Prior radiotherapy to the brain
  • History of brain metastases
  • Pregnancy or lactation

Treatment and study plan

prophylactic cranial irradiation (PCI)

Radiation

Prophylactic cranial irradiation (PCI): 25 Gy in 10 daily fractions, five times a week

Hippocampal avoidance PCI

Radiation

Hippocampal avoidance prophylactic cranial irradiation 25 Gy in 10 daily fractions, five times a week

Primary outcomes

  1. Neurocognitive functioning (NCF) (Free and Cued Selective Reminding Test)

    Time frame: Change from baseline to 3 months

    Free and Cued Selective Reminding Test (FCSRT) evaluated at baseline and 3 months after radiation

Secondary outcomes

  1. Neurocognitive functioning (NCF) (Free and Cued Selective Reminding Test)

    Time frame: Change from baseline to 6,12 and 24 months

    Free and Cued Selective Reminding Test (FCSRT) evaluated at baseline and 6,12 and 24 months after radiation

  2. Hippocampus brain metastases (brain magnetic resonance imaging) (MRI)

    Time frame: Change from baseline to 3, 6,12 and 24 months

    Evaluation of hippocampus brain metastases at 3, 6, 12 and 24 months after radiation

  3. Hippocampus volume (brain magnetic resonance imaging) (MRI)

    Time frame: Change from baseline to 3, 6,12 and 24 months

    Evaluation of hippocampus volume at 3, 6, 12 and 24 months after radiation

  4. Adverse effects (according to Common Toxicity Criteria for Adverse Effects)

    Time frame: Change from baseline to 3, 6,12 and 24 months

    Evaluation of adverse effects according to Common Toxicity Criteria for Adverse Effects (NCI-CTCAE) version 4.0 at 3, 6, 12 and 24 months after radiation

  5. Quality of life (measured by European Organization for Research and Treatment of Cancer (EORTC) questionnaire (QLQ C-30 and QLQ BN-20)

    Time frame: Change from baseline to 3, 6,12 and 24 months

    Evaluation of Quality of Life (QoL) measured by European Organization for Research and Treatment of Cancer (EORTC) questionnaire (QLQ C-30 and QLQ BN-20)

  6. Overall survival

    Time frame: Up to 5 years

    From the start date of PCI until the date of death from any cause, or the last follow-up date whichever came first, assessed up to 60months"

Sponsors and collaborators

Lead sponsor

Grupo de Investigación Clínica en Oncología Radioterapia

Other

Registry information

Official study title

Phase III Trial Evaluating Memory Preservation of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance in Small Cell LUNG Cancer (PREMER-TRIAL)

Important dates

Study start
2014
Primary completion
2019
Study completion
2020
First posted
Mar 25, 2015
Registry last updated
Aug 2, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.